Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes.
The objective of this study was to determine the prevalence, mutual associations, clinical manifestations, and diagnoses associated with serum autoantibodies, as detected using recently available immunoassays, in patients with autoimmune myositis (AIM). Sera and clinical data were collected from 100 patients with AIM followed longitudinally. Sera were screened cross-sectionally for 21 autoantibodies by multiplex addressable laser bead immunoassay, line blot immunoassay, immunoprecipitation of in vitro translated recombinant protein, protein A assisted immunoprecipitation, and enzyme-linked immunosorbent assay. Diagnoses were determined using the Bohan and Peter classification as well as recently proposed classifications. Relationships between autoantibodies and clinical manifestations were analyzed by multiple logistic regression. One or more autoantibodies encompassing 19 specificities were present in 80% of the patients. The most common autoantibodies were anti-Ro52 (30% of patients), anti-Ku (23%), anti-synthetases (22%), anti-U1RNP (15%), and anti-fibrillarin (14%). In the presence of autoantibodies to Ku, synthetases, U1RNP, fibrillarin, PM-Scl, or scleroderma autoantigens, at least one more autoantibody was detected in the majority of sera and at least two more autoantibodies in over one-third of sera. The largest number of concurrent autoantibodies was six autoantibodies. Overall, 44 distinct combinations of autoantibodies were counted. Most autoantibodies were unrestricted to any AIM diagnostic category. Distinct clinical syndromes and therapeutic responses were associated with anti-Jo-1, anti-fibrillarin, anti-U1RNP, anti-Ro, anti-Ro52, and autoantibodies to scleroderma autoantigens. We conclude that a significant proportion of AIM patients are characterized by complex associations of autoantibodies. Certain myositis autoantibodies are markers for distinct overlap syndromes and predict therapeutic outcomes. The ultimate clinical features, disease course, and response to therapy in a given AIM patient may be linked to the particular set of associated autoantibodies. These results provide a rationale for patient profiling and its application to therapeutics, because it cannot be assumed that the B-cell response is the same even in the majority of patients in a given diagnostic category.
Koenig
Martial
M
University of Montreal School of Medicine, and Laboratory for Research in Autoimmunity, Centre Hospitalier de l'Université de Montréal, M-4243, 1560 East Sherbrooke Street, Montreal, Quebec, Canada H2L 4M1.
Fritzler
Marvin J
MJ
Targoff
Ira N
IN
Troyanov
Yves
Y
Senécal
Jean-Luc
JL
D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood*; D001324:Autoantigens / Q000276:immunology*; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000276:immunology*; D003430:Cross-Sectional Studies; D018604:Epitope Mapping; D000939:Epitopes / Q000276:immunology*; D006801:Humans; D007118:Immunoassay; D009220:Myositis / Q000175:diagnosis / Q000276:immunology*
D000974:Antibodies, Antinuclear; D001324:Autoantigens; D000939:Epitopes
J Immunol Methods. 2000 Sep 21;243(1-2):243-55
10986418
Neurology. 2003 Aug 12;61(3):288-9
12913184
Rheumatology (Oxford). 2001 Oct;40(10):1157-62
11600746
Arthritis Rheum. 2001 Oct;44(10):2367-70
11665978
Medicine (Baltimore). 2002 Mar;81(2):154-67
11889414
Semin Neurol. 2002 Mar;22(1):41-51
12170392
Rheum Dis Clin North Am. 2002 Nov;28(4):859-90, viii
12506776
Arthritis Rheum. 2003 Jan;48(1):203-9
12528120
Arthritis Rheum. 2003 Jan;48(1):210-7
12528121
Neurology. 2003 Aug 12;61(3):316-21
12913190
Lancet. 2003 Nov 22;362(9397):1762-3; author reply 1763
14643132
J Mol Med (Berl). 2003 Dec;81(12):811-8
14598044
Arthritis Rheum. 2004 Oct;50(10):3265-74
15476238
N Engl J Med. 1975 Feb 20;292(8):403-7
1089199
N Engl J Med. 1975 Feb 13;292(7):344-7
1090839
Arthritis Rheum. 1984 Oct;27(10):1150-6
6386003
Arthritis Rheum. 1985 Jul;28(7):796-803
2409985
Arthritis Rheum. 1988 Oct;31(10):1322-7
3052460
Clin Exp Immunol. 1989 Jun;76(3):366-72
2665976
J Immunol. 1990 Mar 1;144(5):1737-43
2307838
Arthritis Rheum. 1990 Sep;33(9):1361-70
2403400
Medicine (Baltimore). 1991 Nov;70(6):360-74
1659647
Arthritis Rheum. 1992 Jan;35(1):95-100
1731817
Arthritis Rheum. 1992 Apr;35(4):449-56
1567494
Medicine (Baltimore). 1992 Nov;71(6):327-36
1435228
J Clin Invest. 1993 Jun;91(6):2556-64
8514867
Arthritis Rheum. 1993 Aug;36(8):1121-7
8343187
J Cell Biol. 1993 Dec;123(6 Pt 1):1345-54
8253835
Arthritis Rheum. 1994 Feb;37(2):248-52
8129780
J Immunol. 1995 Jan 15;154(2):961-71
7529293
J Rheumatol. 1995 Apr;22(4):581-5
7791146
J Clin Invest. 1995 Oct;96(4):1730-7
7560064
Br J Rheumatol. 1996 Apr;35(4):305-6
8624632
Arthritis Rheum. 1996 Jul;39(7):1151-60
8670324
Clin Immunol Immunopathol. 1996 Oct;81(1):41-7
8808640
Arthritis Rheum. 1996 Sep;39(9):1507-18
8814062
Arthritis Rheum. 1997 Jul;40(7):1257-66
9214426
Clin Exp Immunol. 1997 Jul;109(1):32-40
9218821
Curr Opin Rheumatol. 1997 Nov;9(6):527-35
9375282
J Rheumatol. 1999 Mar;26(3):563-7
10090163
Arthritis Rheum. 1999 May;42(5):899-909
10323445
Reumatismo. 2005 Jan-Mar;57(1):22-8
15776143
Medicine (Baltimore). 2005 Jul;84(4):231-49
16010208
Arthritis Rheum. 2005 Aug;52(8):2425-32
16052583
Semin Arthritis Rheum. 2005 Aug;35(1):35-42
16084222
Ann Rheum Dis. 2006 Feb;65(2):242-5
16410528
Autoimmunity. 2006 May;39(3):217-21
16769655
Lupus. 2006;15(7):422-7
16898176
Clin Immunol. 2006 Sep;120(3):349-56
16644287
Ann Rheum Dis. 2001 Feb;60(2):116-23
11156543